학술논문
IDF21-0338 Results of Randomized Double Blind Phase III trial of FDC of Remogliflozin Etabonate and Teneligliptin in T2DM patients
Document Type
Abstract
Author
Source
In Diabetes Research and Clinical Practice April 2022 186 Supplement 1
Subject
Language
ISSN
0168-8227